



## **INSTALLATION OF IBA PROTON SYSTEM BEGINS AT ATreP IN TRENTO, ITALY**

**Trento, Italy, May 3, 2012** — Installation of an IBA cyclotron, beam line and two state-of-the-art patient treatment rooms has begun at Italy's most advanced cancer center, the Agenzia Provinciale Per la Protonterapia (ATreP), being constructed in Trento.

IBA engineers expect the proton beam system and first patient treatment room to be ready for commissioning by ATreP staff in about one year. Commissioning is a monthlong process that includes confirming proton beam uniformity and accuracy, and integrating imaging into the proton targeting system. It is the final stage before clinicians at the facility can begin killing cancerous tumors with proton beams.

ATreP will house two gantry treatment rooms and a research room. Each of the treatment rooms will be equipped with the latest advance in IBA's Pencil Beam Scanning dedicated nozzle. With a beam spot as fine as 3 millimeters, Pencil Beam Scanning permits high-definition conformity to the tumor and rapid dose delivery.

The facility has been designed in collaboration with Impresa di Costruzioni Ing. E. Mantovani S.P.A. of Padova, Italy.

ATreP was established by the autonomous Province of Trento in 2004. The three-story facility will be managed by the Provincial Health Service.

As access to proton therapy increases around the world, IBA continues to demonstrate compassionate innovations with more patient-friendly treatment rooms and more precise therapies. To date, IBA proton systems are part of more than half of the world's clinically based proton therapy facilities. They include 12 operational proton therapy centers worldwide, and nine more centers in development.

Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and sparing healthy surrounding tissue.

### **ABOUT IBA**

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for health care with a focus on cancer diagnosis and therapy. Leveraging its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.

*Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.*

*(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).*

Website: [www.iba-worldwide.com](http://www.iba-worldwide.com)



Contact

**IBA**

**Bill Hansen**

Director of Global Marketing

p. 00-1-612-804-5559

e. [William.Hansen@iba-group.com](mailto:William.Hansen@iba-group.com)